New DCVax-L brain cancer vaccine trial starts enrolling

Another site in the U.S., Hoag Memorial Hospital Presbyterian in Orange County, CA, has begun recruiting for a Phase II clinical trial of Northwest Biotherapeutics' ($NWBO) DCVax-L personalized brain cancer vaccine for the treatment of glioblastoma multiforme, the most aggressive and lethal form of brain cancer. By the end of February 2012, Northwest Biotherapeutics had 30 sites open and recruiting in the U.S., and the company plans for 40 by the end of the second quarter. DCVax-L is made from the patient's blood and tumor tissue. In January 2011, FierceVaccines reported that Northwest Biotherapeutics had restarted recruitment into Phase II trials after a two-year postponement, because of the company's cash issues. Press release

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.